Matthew D. Wright, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint Appointment), Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, The Woodlands, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Georgetown University School of Medicine, Washington, DC, US, MD |
| 2012 | Case Western Reserve University, Cleveland, Ohio, US, Bachelor of Arts in Biology, BA |
| 2012 | Case Western Reserve University, Cleveland, Ohio, US, Bachelor of Arts in Spanish, BA |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio |
| 2016-2019 | Clinical Residency, Internal Medicine, Case Western Reserve University/University Hospitals, Cleveland, Ohio |
Board Certifications
| 2022 | BLS |
| 2021 | DEA |
| 2019 | American Board of Internal Medicine, Certification in Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Program Director, Medical Oncology Clinical Observer Program, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Senator, Department of Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Other Appointments/Responsibilities
Member, Cleveland Clinic Internal Medicine Residency Hematology-Oncology Interest Group, Cleveland, OH, 2021 - 2022
Member, Cleveland Clinic Hematology-Oncology Program Evaluation Committee, Cleveland, OH, 2020 - 2022
Hufnagel Society M4 Council Representative, Georgetown Learning Societies, Washington, DC, 2015 - 2016
Institutional Committee Activities
Member, Faculty Senate Travel Subcommittee, 2025 - Present
Member, Medical Records Committee, 2023 - Present
Honors & Awards
| 2024 | MDACC Patient Experience Award: Top 10% Provider, MD Anderson Cancer Center |
| 2020 | Cleveland Clinic Caregiver Appreciation Award (3) |
| 2014 | McVay Scholarship |
| 2012 | Phi Beta Kappa, National Academic Honor Society |
| 2012 | Sigma Delta Pi, National Collegiate Hispanic Studies Honor Society |
| 2012 | Summa cum laude, Case Western Reserve University |
| 2011 | Outstanding Junior Arts & Sciences |
| 2011 | Mortar Board, National Collegiate Honor Society |
| 2010 | Phi Beta Kappa Prize |
| 2008 - 2012 | President's Scholarship |
| 2008 | Bishop Lamb Award |
| 2008 | Leaders of Tomorrow Award |
| 2008 | President's Award (Co-Valedictorian) |
| 2007 | Senior Class President |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, Li Y, Demanelis K, Ramaswamy B, Tseng G, Lee AV, Williams N, Kruse M. Clinicopathological Features and Outcomes Comparing Patients with Invasive Ductal and Lobular Breast Cancer. J Natl Cancer Inst 114(11):1511-1522, 2022. e-Pub 2022. PMID: 36239760.
- Varma R, Wright M, Abraham J, Kruse M. Immune Checkpoint Inhibition in Early-stage Triple-negative Breast Cancer. Expert Rev Anticancer Ther 22(11):1225-38, 2022. e-Pub 2022. PMID: 36278877.
- Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, Valente SA. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Ann Surg Oncol 28(10):5723-5729, 2021. e-Pub 2021. PMID: 34324111.
- Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental Outcomes of Cord Blood Transplantation for Krabbe Disease: A 15-year study. Neurology 89(13):1365-1372, 2017. e-Pub 2017. PMID: 28855403.
Other Articles
- Wright MD, Abraham MJ Preclinical Discovery and Development of Abemaciclib used to Treat Breast Cancer. Expert Opin Drug Discov 16(5):485-496, 2021. PMID: 33280445.
Abstracts
- Nelson AA, Wright MD, Khaki AR, Diamantopoulos LK, Kyasaram RK, Nezami B, Dawsey S, Patel K, Eitman C, MacLennan G, Grivas P, Mendiratta P, Ponsky LE, Hoimes CJ. Association of Early Bone Metastases and Outcomes of the Bone Predominant Metastatic Urothelial Carcinoma (BPmUC) Phenotype. J Clin Oncol 37, 2019. e-Pub 2019.
- Nelson AA, Opneja A, Nezami BG, Ponsky LE, Wright MD, Mergler P, Kyasaram RK, Eitman C, Patel K, MacLennan G, Cooney MM, Grivas P, Barata PC, Garcia JA, Fu P, Hoimes CJ. Patterns of Metastases, Treatment (tx), and Outcomes in Bone Predominant (BP) Metastatic Urothelial Carcinoma (mUC). J Clin Oncol 36, 2018. e-Pub 2018.
- Dempster MS, Wright MD, Cocco D, ElSherif AS, Valente SA, Li H, Kruse ML. Comparison of Gene Expression Profiling Results and Clinical Outcomes Among Patients with Pleomorphic ILC and Classic ILC.
- Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Comparison of Clinical Features and Outcomes for Pleomorphic Invasive Lobular Carcinoma vs. Non-pleomorphic Invasive Lobular Carcinoma.
- Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Assessing the Impact of Preoperative Breast MRI on Time to Treatment for Invasive Lobular Carcinoma.
Selected Presentations & Talks
Regional Presentations
- 2021. Assessing the Impact of Preoperative Breast MRI on Time to Treatment for Invasive Lobular Carcinoma. Invited. San Antonio, TX, US.
- 2021. Comparison of Clinical Features and Outcomes for Pleomorphic Invasive Lobular Carcinoma vs. Non-pleomorphic Invasive Lobular Carcinoma. Invited. San Antonio, TX, US.
- 2021. Comparison of Gene Expression Profiling Results and Clinical Outcomes Among Patients with Pleomorphic ILC and Classic ILC. Invited. San Antonio, TX, US.
National Presentations
- 2021. Invasive Lobular Breast Cancer: Data to Guide Surgical Decision Making. Invited. 22nd Annual Meeting Virtual Conference, US.
- 2020. Lecture. Invited. Morbidity and Mortality Conference. Cleveland, OH, US.
- 2019. Immunotherapy Toxicity. Invited. Senior Grand Rounds. Cleveland, OH, US.
- 2018. Outcomes in Bone Predominant (BP) Urothelial Carcinoma (UC). Invited. Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2016. Recurrence of a Rare Malignancy Manifesting as Multiple Cutaneous Lesions. Invited. Washington, DC, US.
Patient Reviews
CV information above last modified April 02, 2025